MS
JUNO

Marshall & Sullivan’s Juno Therapeutics, Inc. JUNO Stock Holding History

Marshall & Sullivan’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-125
Closed -$5K – 64
2016
Q1 		$5K Hold
125
– – 0.01% 56
2015
Q4 		$5K Hold
125
– – 0.01% 56
2015
Q3 		$4K Buy
+125
New +$5.48K 0.01% 58

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall & Sullivan's JUNO Position: Q2 2016 in Review

Marshall & Sullivan sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2016, closing a stake of 125 shares — an estimated $5K sold.

Marshall & Sullivan first reported a position in JUNO in Q3 2015 and held it in 3 quarters. The position peaked at $5K in Q1 2016. 170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

  • Marshall & Sullivan reported no remaining Juno Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Marshall & Sullivan sold 125 Juno Therapeutics, Inc. shares in Q2 2016, an estimated $5K.
  • Marshall & Sullivan first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 3 quarters.
  • Marshall & Sullivan's Juno Therapeutics, Inc. position peaked at $5K in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on Marshall & Sullivan's 13F filing for Q2 2016, filed 12 Aug 2016.